The University of North Carolina at Chapel Hill School of Medicine, 231 MacNider Hall, CB# 7225, Chapel Hill, NC, 27599-7225, USA.
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Pediatr Nephrol. 2021 May;36(5):1307-1310. doi: 10.1007/s00467-021-04919-x. Epub 2021 Feb 5.
The number of medications could serve as a surrogate for burden of care at home and may affect health-related quality of life (HRQoL) in children with chronic kidney disease (CKD).
Using baseline data from the Chronic Kidney Disease in Children (CKiD) Study, we modeled HRQoL scores, self-reported by the child (if ≥ 8 years old) and/or caregiver (all children) on unique counts and administrations of CKD- and non-CKD-related medications, using multivariate linear regression. Heterogeneity of associations between HRQoL and medication burden by age group (≥ 8 vs. < 8 years old) were explored.
734 participants median age 11 years, disease duration 8 years, median eGFR 53 mL/min/1.73 m, 61% male, 22% African-American, 31% glomerular disease were prescribed median 3 unique CKD-related medications. Regarding HRQoL assessment, 201 children were < 8 years old and had only parent-proxy HRQoL score; 533 children ≥ 8 years of age had both child and parent-proxy scores. Overall, parents of children < 8 years old reported higher HRQoL scores than parents of older children: 84 vs. 76. However, in a unified multivariate regression model, HRQoL scores of children < 8 years showed greater decreases as the number of CKD-related medications increased compared to scores for children ≥ 8 years old.
Average HRQoL scores reported by parents of younger CKD children were higher than those of older CKD children but decreased more with increased CKD medication counts than scores of older children. Considerations of HRQoL may be of particular importance for clinicians and caregivers when managing chronic disease comorbidities in younger children.
药物的数量可以作为家庭护理负担的替代指标,并可能影响慢性肾脏病(CKD)儿童的健康相关生活质量(HRQoL)。
使用慢性肾脏病儿童(CKiD)研究的基线数据,我们使用多元线性回归模型,对儿童(如果≥ 8 岁)和/或照顾者(所有儿童)自我报告的 HRQoL 评分进行建模,该评分基于 CKD 和非 CKD 相关药物的独特计数和管理。探讨了 HRQoL 与药物负担之间的关联在年龄组(≥ 8 岁与< 8 岁)之间的异质性。
734 名参与者的中位年龄为 11 岁,疾病持续时间为 8 年,中位 eGFR 为 53 ml/min/1.73 m,61%为男性,22%为非裔美国人,31%为肾小球疾病,共开了 3 种中位数的 CKD 相关药物。关于 HRQoL 评估,201 名儿童< 8 岁,仅接受父母代理 HRQoL 评分;533 名≥ 8 岁的儿童同时接受儿童和父母代理评分。总的来说,< 8 岁儿童的父母报告的 HRQoL 评分高于年龄较大的儿童的父母:84 分对 76 分。然而,在统一的多元回归模型中,与≥ 8 岁的儿童相比,< 8 岁的 CKD 儿童的 HRQoL 评分随着 CKD 相关药物数量的增加而下降得更大。
与年龄较大的 CKD 儿童相比,年龄较小的 CKD 儿童的父母报告的平均 HRQoL 评分更高,但随着 CKD 药物数量的增加,评分下降幅度大于年龄较大的儿童。在管理年幼儿童的慢性疾病合并症时,考虑 HRQoL 可能对临床医生和照顾者特别重要。